Hedge Fund · CIK 0001035674

John Paulson

Paulson & Co
Share

John Paulson runs Paulson & Co, a hedge fund overseeing $3.26B in disclosed equity holdings (SEC CIK 0001035674). The latest portfolio (2025Q4) discloses 9 positions across 4 sectors, with the largest positions in MDGL, PPTA and BHC. On a mark-to-market basis the tracked portfolio has returned 95.4% over the past year. OpenStocks tracks 40 consecutive quarterly snapshots for this manager — every position change, new entry, and exit is logged below.

Portfolio
$3.26B
Positions
9
Quarter
2025Q4
Filings tracked
40
1Y+95.4%3Y+296.6%5Y+308.6%10Y-10.8%Full performance →
Biggest winner since filing
PPTAPERPETUA RESOURCES CORP
+304.6%
+$632.2M
Biggest loser since filing
BHCBAUSCH HEALTH COS INC
-53.8%
−$181.8M

Investment strategy

John Paulson is a mid-size fund with a highly concentrated portfolio tilted toward healthcare names. 54% of the disclosed equity book is in Healthcare.

Embed this chart
Paste this iframe anywhere to embed the live MDGL chart.
<iframe src="https://openstocks.me/embed/stock/MDGL" width="100%" height="480" frameborder="0" loading="lazy" title="MDGL chart by OpenStocks" style="border:0;border-radius:12px;background:transparent"></iframe>

Holdings

5 sectors
16 positions
Top 3 = 67% of book · MDGL, AAMI, BHC
View full portfolio →

Performance

vs SPY
40 quarters tracked
Mark-to-market portfolio growth vs SPY benchmark, with AUM and concentration history.
View performance →

Options & derivatives

No options
John Paulson has no PUT or CALL positions disclosed for this quarter.
View options →

Activity & trades

Quarter-by-quarter
Last move 2025Q4
ADD BHC — and 4 more recent moves.
View activity →

Recent transactions

See full activity →
ADD
BAUSCH HEALTH COS INC
+2,500,000
~$6.95 · 2025Q4
2026-02-17
SOLD
HONEYWELL INTL INC
200,000
~$210.50 · 2025Q4
2026-02-17
TRIM
MADRIGAL PHARMACEUTICALS INC
200,001
~$582.34 · 2025Q4
2026-02-17
ADD
THRYV HLDGS INC
+67,070
~$6.05 · 2025Q4
2026-02-17
SOLD
TRILOGY METALS INC NEW
14,326,996
~$2.10 · 2025Q4
2026-02-17